Review Article

Antioxidative Property and Molecular Mechanisms Underlying Geniposide-Mediated Therapeutic Effects in Diabetes Mellitus and Cardiovascular Disease

Table 3

Preclinical evidence of therapeutic potential from geniposide.

SystemDisorderModelDoseAdministration routePharmacological actionReference

Endocrine systemType 2 DMSpontaneously obese
 Type 2 diabetic TSOD mice
0.1% and 0.3%Intragastric administrationReducing the body weight and visceral fat accumulation and alleviating abnormal lipid metabolism and intrahepatic lipid accumulation[16]
Type 2 DMFree fatty acid-treated HepG2 cells10, 50, 100 μMIncubationBlocking the accumulation of intracellular lipid resulted from the free fatty acid treatment and enhanced the PPARα expression[16]
Type 2 DMHepG2 cell model of insulin resistance15.63-125 mg/LIncubationPromoting autophagy and inhibiting insulin resistance in the HepG2 cells, which may be associated with the dynamic regulation of the P62/NF-κB/GLUT-4 pathway[123]
Type 2 DMPalmitate-treated INS-1 cells1, 10, 100 μMIncubationRelieving β-cell apoptosis via activation of the GLP-1 receptor[132]
Type 2 DMCultured mouse islets after challenge with diabetic stimuli20 μMIncubationPromoting β regeneration and survival via regulating β-catenin/TCF7L2 pathway[132]
Type 2 DMHepG2 cells1, 10, 100 μMIncubationSuppressing hepatic glucose production via AMPK signaling pathway[137]
Type 1or 2 DMHigh glucose-induced glucotoxic insulinoma cells10 μMIncubationImproving β-cell function and increasing the proliferation of β-cells exposed to prolonged hyperglycemia[128]
Type 1 DMRat pancreatic islets10 μMIncubationStimulating insulin secretion in pancreatic β-cells by regulating GLP-1 receptor/cAMP signaling and Ca2+ channels[133]
Type 1 DMRat pancreatic INS-1 cells10 μMIncubationEnhancing glucose uptake via activating AMPK in pancreatic β cells[138]
Diabetic nephropathyDiabetic rats induced by streptozotocin50, 100 mg/kg/dIntragastric administrationSuppressing NF-κB mediated inflammation response[135]

Cardiovascular systemMyocardium I/RHypoxia/reoxygenation-induced H9c2 Cells10, 20, 40, 80 μMIncubationEnhancing mitochondrial function via the GLP-1 receptor mediated the PI3K/Akt signaling pathway[10]
AtherosclerosisApoE−/− mice fed a high-cholesterol diet100 mg/kg/dOral administrationIncreasing proliferation of smooth muscle cells and suppressing inflammation[94]
AtherosclerosisApoE−/− mice fed a high-cholesterol diet100 mg/kg/dOral administrationDecreasing the dendritic cells numbers and inhibiting dendritic cell maturation in bone marrow and infiltration into lesions[99]
AtherosclerosisApoE−/− mice fed a high-cholesterol diet100 mg/kg/dOral administrationRegulating lipid and promoting the number and function of Treg cells[103]
Cardiac hypertrophyMice with transverse aortic constriction50 mg/kg/dOral administrationActivating the GLP-1 receptor/AMPKα pathway, inhibiting ERS and oxidative stress[17]
Cardiac fibrosisMice induced by isoprenaline50 mg/kg/dOral administrationSuppressing oxidative stress, ERS, and acetylated Smad3 in a SIRT1-dependent manner and inhibiting the phosphorylated-Samd3 pathway independent of SIRT1 activation[78]
Obesity-related cardiac injuryMice induced by high-fat food50 mg/kg/dOral administrationAlleviating inflammation in a SIRT1-dependent manner and inhibiting cardiomyocyte apoptosis in a AMPKα-dependent manner[92]
Cerebral I/R injuryOGD/R-induced SH-SY5Y cells10 μMIncubationInhibition of endoplasmic reticulum stress and autophagy[108]
Ischemic stroke.tMCAO rats75 mg/kg/dIntraperitoneal injectionsProtecting neurons against post-ischemic neurovascular injury through the activation of GluN2A/AKT/ERK pathways[115]